Clinical data

Back2Sleep: clinical studies and published data

A summary of the studies published on Nastent, the original name of Back2Sleep, in snoring and mild to moderate obstructive sleep apnea, with a few papers on other nasopharyngeal stents.

Scientific summary

Key figures from the scientific literature

The studies published on Nastent show encouraging results in selected patients who snore or have mild to moderate sleep apnea, especially when the obstruction is at the level of the soft palate.

6

Studies on Nastent

Published by hospital and university teams in Japan, France and Switzerland, including two congress posters.

256

People included

In these six studies, including 16 volunteers without sleep apnea.

26% to 35%

Responders

In the two largest studies (101 and 71 patients), more when the obstruction comes from the soft palate.

86.6%

Minimum SpO₂

Minimum oxygen saturation at night with Nastent, versus 81.9% without (Okuno 2019, 29 patients).

Publications

The publications at a glance

The studies published on Nastent, then a few papers on other nasopharyngeal stents.

Study Year Population Main result Access
Hirata & Satoh 2015 6 patients Fewer apneas and hypopneas and better SpO₂ in mild to moderate apnea, limited effect in severe apnea, snoring improved in all DOI
Furuie et al. 2017 (poster) 16 volunteers without sleep apnea, including 9 snorers Discomfort down within a few days (6.1 → 3.2), snoring index 0.260 → 0.040 in the 9 snorers Poster (PDF)
Tendron, Chabolle, Blumen (Hôpital Foch) 2018 11 patients During a sedated endoscopy: AHI 6.0 with the tube, versus 20.5 at the diagnostic test, snoring gone in 10/11 Poster (PDF)
Okuno et al. 2019 30 patients (29 analyzed) REI 22.4 → 15.7, min. SpO₂ 81.9 → 86.6% after one month DOI
Ohtsuka et al. 2021 71 patients AHI, supine AHI, ODI and snoring down. Complete response 25%, partial 10%, both maintained at 1 month. About 30% did not tolerate the device DOI
Dellweg, Kampmann, Tschopp 2022 122 patients (101 analyzed) Responders: 26% overall, 57% in anteroposterior soft palate collapse. No effect on tongue-base or multilevel obstruction. Hard to tolerate DOI, open access
Traxdorf et al. (AlaxoStent, another device) 2016 8 patients AHI 31.1 → 19.0 with the stent, 8.2 with CPAP, over one night DOI
Kumar et al., meta-analysis (nasopharyngeal airways in general) 2015 up to 193 patients AHI 44.1 → 22.7 (193 patients), apnea index 32.4 → 9.0 (53 patients), efficacy and tolerance vary between studies DOI
Yenigun et al. (self-expanding stent, another device) 2020 5 patients Stent placed under endoscopy with sedation: feasibility of soft palate support DOI

ⓘ Sources: articles in scientific journals (DOI links) and two congress posters. AHI = apnea-hypopnea index. Some publications are open access, others require a subscription to the publisher.

Scientific review

Clinical studies on Nastent, the original name of Back2Sleep

(Back2Sleep is the European name of Nastent, which is sold under the name Nastent in Asia)
A summary of the main studies published on Nastent. Papers on other nasopharyngeal stents are presented separately, further down.

Okuno K, Ono Minagi H, Ikai K, et al. The efficacy of nasal airway stent (Nastent) on obstructive sleep apnoea and prediction of treatment outcomes

Journal of Oral Rehabilitation, 2019, 46(1):51-57 (online in 2018). DOI 10.1111/joor.12725 (PMID 30281824).

Prospective study in 30 patients (29 analyzed). Nastent significantly reduces the REI (22.4 → 15.7, p<0.01) and increases minimum SpO₂ (81.9 → 86.6, p<0.01). The related congress abstract (SLEEP 2018, no. 0555) also reports a fall in ESS from 12.1 to 6.7. The ratio of the inferior to middle airway space (IAS/MAS) on the cephalogram predicts treatment response with a sensitivity of 90.9% and a specificity of 88.9%. A velopharynx narrower than the hypopharynx predicts success.

Source: PubMed / DOI

Dellweg A, Kampmann M, Tschopp K. Evaluation of a nasopharyngeal stent in patients with obstructive sleep-related breathing disorders

Journal of International Medical Research, 2022, 50(1):3000605211073302. DOI 10.1177/03000605211073302 (PMID 35062854).

Retrospective study in 122 patients who were not candidates for CPAP: 21 excluded (14 for intolerance, 7 for an unusable recording), 101 analyzed. The Naśtent (distributed in the United Kingdom by Corinium Medical) is inserted by the care team for the first half of the night. The AHI falls on average from 24.6 to 18.5 (−25%). 26% of patients respond to treatment (AHI reduction of more than 50% and AHI below 20), 38% with isolated soft palate obstruction and 57% with anteroposterior soft palate collapse. The tube has no effect on tongue-base or multilevel obstructions. Across the whole group, snoring is not significantly reduced, and a third of the patients analyzed report marked discomfort. Using a 40% fall in the AHI as the threshold, the tube detects 85.7% of the soft palate obstructions identified at endoscopy: it can be used as a diagnostic tool when endoscopy is not available.

Source: PubMed / DOI

Ohtsuka K, Baba R, Yamasawa W, et al. The Effectiveness of Nasal Airway Stent Therapy for the Treatment of Mild-to-Moderate Obstructive Sleep Apnea Syndrome

Respiration, 2021, 100(3):193-200 (online in December 2020). DOI 10.1159/000512319 (PMID 33370725).

Prospective, single-arm, interventional pilot study in 71 patients (AHI 5 to 20), with Nastent. The NAS significantly improves the AHI, the supine AHI, the RDI, the ODI and snoring volume (p<0.001 for most). 25% complete response and 10% partial response, maintained at 1 month. Better sleep quality (PSQI 6.0 → 5.3). About 30% of patients did not tolerate the device (adverse effects).

Source: PubMed / DOI

Hirata Y, Satoh M. Pilot Study of a Nasal Airway Stent for the Treatment on Obstructive Sleep Apnea

Journal of Sleep Disorders & Therapy, 2015, 4(4):1000207. DOI 10.4172/2167-0277.1000207.

Pilot study in 6 subjects. The NAS was tolerated by all subjects, with good adherence. It reduces apneas/hypopneas and improves oxygen saturation in mild to moderate OSA. Snoring improved in all subjects. Conclusion: a possible alternative for patients who cannot tolerate CPAP, or for snorers.

Source: Journal of Sleep Disorders & Therapy, 2015, 4(4):1000207

Furuie W, Sasaki I, Uezato A, et al. Evaluation of the Tolerance and Effectiveness of Nasal Airway Stent

Tokyo Medical and Dental University, congress poster, 2017.

16 volunteers without sleep apnea (AHI of 0 in all), including 9 snorers. Two dropped out. In the other 14, discomfort measured by questionnaire falls from 6.1 to 3.2 between day 4 and day 9. In the 9 snorers, the snoring index goes from 0.260 to 0.040. Some participants gave up because of the discomfort. Device studied: Nastent.

Source: Tokyo Medical and Dental University

Tendron A, Chabolle F, Blumen M. Evaluation of the effectiveness of the nasopharyngeal tube (Nastent®) on snoring and sleep apnea syndrome during drug-induced sleep endoscopy

ENT and Head and Neck Surgery Department, Hôpital Foch (Paris), poster, Congrès du Sommeil, Lille, November 2018.

Prospective study in 11 patients (1 simple snorer, 10 with mild to moderate apnea). The tube is inserted by the physician, under visual control, during an endoscopy under propofol sedation. The AHI measured during this endoscopy is 6.0 ± 19.1 with the tube, versus 20.5 ± 12.6 on diagnostic polygraphy (p < 0.001). Events disappear in all patients except one, who had an epiglottic obstruction. Snoring disappears in 10 of 11 patients. The authors conclude that the tube “may be a good therapeutic alternative” for snoring or minimal to moderate apnea, and that a study during natural sleep is essential to confirm its efficacy.

Source: Hôpital Foch, Paris

Other nasopharyngeal stents

These papers are not about Back2Sleep or Nastent. They are cited to place the technique in context.

Traxdorf M, Hartl M, Angerer F, et al. A novel nasopharyngeal stent for the treatment of obstructive sleep apnea: a case series of nasopharyngeal stenting versus continuous positive airway pressure

European Archives of Oto-Rhino-Laryngology, 2015/2016, 273(5):1307-1312. DOI 10.1007/s00405-015-3815-2 (PMID 26525882).

Single-center study, a series of 8 patients (baseline AHI ≥ 10), comparing the AlaxoStent (a nasopharyngeal stent from another manufacturer) with CPAP over two nights. AHI before treatment 31.1, with the stent 19.0 (−39%), with CPAP 8.2. Obstructive apneas fall by more than 94% with both approaches. The authors estimate the responder rate of the stent at 50%, comparable to surgery, with no complications.

Source: PubMed / DOI

Yenigun A, Tugrul S, Dogan R, et al. A feasibility study in the treatment of obstructive sleep apnea syndrome and snoring: Nasopharyngeal stent

American Journal of Otolaryngology, 2020, 41(6):102460. DOI 10.1016/j.amjoto.2020.102460 (PMID 32247706).

Feasibility study in 5 patients (mild OSA and snoring, isolated retropalatal obstruction), with a self-expanding nitinol stent placed under endoscopy with sedation. The stent stops the soft palate from falling backward. The authors propose it as an alternative to CPAP, oral appliances and surgery.

Source: PubMed / DOI

Systematic review and meta-analysis

Kumar AR, Guilleminault C, Certal V, et al. Nasopharyngeal airway stenting devices for obstructive sleep apnoea: a systematic review and meta-analysis

Journal of Laryngology & Otology, 2014/2015, 129(1):2-10. DOI 10.1017/S0022215114003119.

Search of Medline, Scopus, Web of Science and Cochrane: of 573 potential studies, 16 were included. They cover nasopharyngeal airways in general, not Nastent. Meta-analysis: apnea index 32.4 → 9.0 events/h (53 patients), AHI 44.1 → 22.7 (193 patients), minimum SpO₂ 66.5% → 75.5%. Efficacy and tolerance vary between studies.

Source: PubMed / DOI

Diagnostic use / planning

Victores AJ, Olson K, Takashima M. Interventional Drug-Induced Sleep Endoscopy: A Novel Technique to Guide Surgical Planning for Obstructive Sleep Apnea

Journal of Clinical Sleep Medicine, 2017, 13(2):169-174. DOI 10.5664/jcsm.6438.

41 patients. A standard nasopharyngeal tube was placed during DISE to simulate the removal of palatal collapse. 83% had multilevel obstruction. With the tube in place, 74% showed at least partial improvement and 35% complete resolution of downstream collapse.

Source: PubMed / DOI

Reading across the studies

In the studies on Nastent, in selected patients, the tube reduces the AHI and snoring. The responder rate ranges from 26% to 35% in the two largest studies and reaches 57% when the obstruction is an anteroposterior collapse of the soft palate.

  • Tolerance remains a major limitation: depending on the study, 11% to 30% of patients did not tolerate the tube.
  • Patient selection is essential: the device acts mainly on palatal/retropalatal obstruction.
  • Retrolingual, epiglottic or multilevel obstructions respond less well.